REG - GlaxoSmithKline PLC - Director/PDMR Shareholding

GSKAnnouncement

15/01/2021 15:15

RNS Number : 9117L
  
GlaxoSmithKline PLC
  
15 January 2021
  
 

GlaxoSmithKline plc (the 'Company')
 
Transaction notification
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Ms E Walmsley




b)


Position/status


Chief Executive Officer




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882




b)


Nature of the transaction


Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 14 January 2021, on shares held through the Company's Share Reward Plan.




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£13.8719


28


 




 


 


 


 




d)


Aggregated information
 


N/A (single transaction)
 




 
Aggregated volume Price


 




e)


Date of the transaction


2021-01-14




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr R Connor




b)


Position/status


President, Global Vaccines




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882




b)


Nature of the transaction


Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 14 January 2021, on shares held through the Company's Share Reward Plan.




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£13.8719


84


 




 


 


 


 




d)


Aggregated information
 


N/A (single transaction)
 




 
Aggregated volume Price


 




e)


Date of the transaction


2021-01-14




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Ms D Conrad




b)


Position/status


SVP, Human Resources




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882




b)


Nature of the transaction


Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 14 January 2021, on shares held through the Company's Share Reward Plan.




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£13.8719


4


 




 


 


 


 




d)


Aggregated information
 


N/A (single transaction)
 




 
Aggregated volume Price


 




e)


Date of the transaction


2021-01-14




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr J Ford




b)


Position/status


SVP & General Counsel




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882




b)


Nature of the transaction


Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 14 January 2021, on shares held through the Company's Share Reward Plan.




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£13.8719


2


 




 


 


 


 




d)


Aggregated information


N/A (single transaction)
 




 
Aggregated volume Price


 




e)


Date of the transaction


2021-01-14




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr N Hirons




b)


Position/status


SVP, Global Ethics & Compliance




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882




b)


Nature of the transaction


Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 14 January 2021, on shares held through the Company's Share Reward Plan.




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£13.8719


19


 




 


 


 


 




d)


Aggregated information
 


N/A (single transaction)
 




 
Aggregated volume Price


 




e)


Date of the transaction


2021-01-14




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Ms S Jackson




b)


Position/status


SVP, Global Communications and CEO Office




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882




b)


Nature of the transaction


Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 14 January 2021, on shares held through the Company's Share Reward Plan.




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£13.8719


77


 




 


 


 


 




d)


Aggregated information
 


N/A (single transaction)
 




 
Aggregated volume Price


 




e)


Date of the transaction


2021-01-14




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr D Jackson




b)


Position/status


PCA of Ms S Jackson (SVP, Global Communications and CEO Office)




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882




b)


Nature of the transaction


Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 14 January 2021, on shares held through the Company's Share Reward Plan.




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£13.8719


28


 




 


 


 


 




d)


Aggregated information
 


N/A (single transaction)
 




 
Aggregated volume Price


 




e)


Date of the transaction


2021-01-14




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr L Miels




b)


Position/status


President, Global Pharmaceuticals




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882




b)


Nature of the transaction


Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 14 January 2021, on shares held through the Company's Share Reward Plan.




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£13.8719


4


 




 


 


 


 




d)


Aggregated information
 


N/A (single transaction)
 




 
Aggregated volume Price


 




e)


Date of the transaction


2021-01-14




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr D Redfern




b)


Position/status


Chief Strategy Officer




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882




b)


Nature of the transaction


Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 14 January 2021, on shares held through the Company's Share Reward Plan.




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£13.8719


94


 




 


 


 


 




d)


Aggregated information
 


N/A (single transaction)
 




 
Aggregated volume Price


 




e)


Date of the transaction


2021-01-14




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr R Simard




b)


Position/status


President, Pharmaceuticals Supply Chain




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882




b)


Nature of the transaction


Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 14 January 2021, on shares held through the Company's Share Reward Plan.




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£13.8719


28


 




 


 


 


 




d)


Aggregated information
 


N/A (single transaction)
 




 
Aggregated volume Price


 




e)


Date of the transaction


2021-01-14




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr P C Thomson




b)


Position/status


President, Global Affairs




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882




b)


Nature of the transaction


Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 14 January 2021, on shares held through the Company's Share Reward Plan.




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£13.8719


56


 




 


 


 


 




d)


Aggregated information
 


N/A (single transaction)
 




 
Aggregated volume Price


 




e)


Date of the transaction


2021-01-14




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Ms D Waterhouse




b)


Position/status


Chief Executive Officer of ViiV Healthcare




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882




b)


Nature of the transaction


Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 14 January 2021, on shares held through the Company's Share Reward Plan.




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£13.8719


76


 




 


 


 


 




d)


Aggregated information
 


N/A (single transaction)
 




 
Aggregated volume Price


 




e)


Date of the transaction


2021-01-14




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Ms V Whyte




b)


Position/status


Company Secretary




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882




b)


Nature of the transaction


Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 14 January 2021, on shares held through the Company's Share Reward Plan.




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£13.8719


69


 




 


 


 


 




d)


Aggregated information
 


N/A (single transaction)
 




 
Aggregated volume Price


 




e)


Date of the transaction


2021-01-14




f)


Place of the transaction
 


London Stock Exchange (XLON)




 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
DSHEELFFFFLFBBB